Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Other Events

Item 8.01 Other Events.

On February8, 2017, Synergy Pharmaceuticals Inc. (the Company)
issued a press release announcing that Marino Garcia, the
Companys EVP and Chief Strategy Officer, will participate in a
fireside chat at Leerink Partners 6th Annual Global Healthcare
Conference on Wednesday, February15, 2017 at 11:00 a.m.Eastern
Time).

The press release is attached as Exhibit99.1 to this report on
Form8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and
Exhibits.

(d) Exhibits.

About Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company’s uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Recent Trading Information

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) closed its last trading session up +0.07 at 6.19 with 5,636,036 shares trading hands.